Journal: Journal of Immunology Research

Article Title: Fel d1 Blocking Antibodies: A Novel Method to Reduce IgE-Mediated Allergy to Cats

doi: 10.1155/2021/5545173

Figure Lengend Snippet: Chimeric ELISA evaluation of a rabbit polyclonal anti-Fel d1 antibody (indoor) and rabbit monoclonal anti-Fel d1 (FGI) on IgE binding in different plasma samples. Chimeric ELISA analysis of IgE blocking effect of rabbit anti-Fel d1 polyclonal “Indoor Poly” (Indoor Biotechnologies, Cat# PA-FD1) and rabbit anti-Fel d1 monospecific “FGI” antibodies (FabGennix International, Cat# FELD1-121AP). Both antibodies were tested at serial dilutions of 1 : 20 to 1 : 2,000,000. Cat saliva samples incubated with buffer only (none) showed high Fel d1-to-IgE binding in cat allergic plasma, but not in noncat allergic plasma and nonallergic plasma. Binding of Fel d1 in cat allergic human plasma was reduced by Indoor Poly versus control (none) at dilutions to 1 : 2000 ( p < 0.001) but was not affected by the FGI antibody ( p > 0.10). With noncat allergic and nonallergic plasma, Fel d1 capture was unaffected by all antibodies. ∗ Significantly different from control ( p < 0.001).

Article Snippet: We selected two commercially available rabbit anti-Fel d1 antibodies for initial assessment: Indoor Poly (Indoor Technologies Inc., Cat# PA-FD1) and “FGI” antibodies (FabGennix International, Cat# FELD1-121AP).

Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay, Clinical Proteomics, Blocking Assay, Incubation, Control

Journal: Journal of Immunology Research

Article Title: Fel d1 Blocking Antibodies: A Novel Method to Reduce IgE-Mediated Allergy to Cats

doi: 10.1155/2021/5545173

Figure Lengend Snippet: Beta-hexosaminidase release assay with multiple rabbit Fel d1 antibodies and control serum. “Indoor Poly” dose-dependently reduced relative mediator release in the rat basophil assay compared to a “no-antibody” control. Control rabbit serum, FGI, and Fel d1-specific monoclonal (clone 6F9) had no effect on relative mediator release. ∗ Significantly different from control ( p < 0.001). ∗∗ Significantly different from control ( p < 0.05).

Article Snippet: We selected two commercially available rabbit anti-Fel d1 antibodies for initial assessment: Indoor Poly (Indoor Technologies Inc., Cat# PA-FD1) and “FGI” antibodies (FabGennix International, Cat# FELD1-121AP).

Techniques: Release Assay, Control

Journal: Journal of Immunology Research

Article Title: Fel d1 Blocking Antibodies: A Novel Method to Reduce IgE-Mediated Allergy to Cats

doi: 10.1155/2021/5545173

Figure Lengend Snippet: Beta-hexosaminidase release assay with multiple cat saliva samples. The Indoor Poly antibody dose-dependently reduced Fel d1-to-IgE binding and mediator release in multiple cat saliva samples. Although responses differed across samples, there was a dose-dependent decrease in mediator release across saliva samples at dilutions to 1 : 200 ( p < 0.05). ∗ Significantly different from control ( p < 0.001). ∗∗ Significantly different from control ( p < 0.05).

Article Snippet: We selected two commercially available rabbit anti-Fel d1 antibodies for initial assessment: Indoor Poly (Indoor Technologies Inc., Cat# PA-FD1) and “FGI” antibodies (FabGennix International, Cat# FELD1-121AP).

Techniques: Release Assay, Binding Assay, Control

Journal: Journal of Immunology Research

Article Title: Fel d1 Blocking Antibodies: A Novel Method to Reduce IgE-Mediated Allergy to Cats

doi: 10.1155/2021/5545173

Figure Lengend Snippet: Chimeric ELISA evaluation of chicken egg anti-Fel d1 IgY antibodies on IgE binding compared to egg IgY antibodies from nonimmunized chickens. Anti-Fel d1 IgY antibodies dose-dependently inhibited binding to Fel d1-specific IgE ( ∗ p < 0.001) while preimmune IgY had no inhibitory action. ∗ Significantly different from control ( p < 0.001).

Article Snippet: We selected two commercially available rabbit anti-Fel d1 antibodies for initial assessment: Indoor Poly (Indoor Technologies Inc., Cat# PA-FD1) and “FGI” antibodies (FabGennix International, Cat# FELD1-121AP).

Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay, Control

Journal: Journal of Immunology Research

Article Title: Fel d1 Blocking Antibodies: A Novel Method to Reduce IgE-Mediated Allergy to Cats

doi: 10.1155/2021/5545173

Figure Lengend Snippet: Beta-hexosaminidase release assay with chicken egg anti-Fel d1 antibodies compared to egg IgY antibodies from nonimmunized chickens. The anti-Fel d1 IgY antibody dose-dependently reduced mediator release in the rat basophil assay compared to a “no-antibody” control while preimmune IgY had no effect. ∗ Significantly different from control ( p < 0.001).

Article Snippet: We selected two commercially available rabbit anti-Fel d1 antibodies for initial assessment: Indoor Poly (Indoor Technologies Inc., Cat# PA-FD1) and “FGI” antibodies (FabGennix International, Cat# FELD1-121AP).

Techniques: Release Assay, Control

Journal: PLoS ONE

Article Title: The POZ-ZF Transcription Factor Kaiso (ZBTB33) Induces Inflammation and Progenitor Cell Differentiation in the Murine Intestine

doi: 10.1371/journal.pone.0074160

Figure Lengend Snippet: Cell proliferation was evaluated by Ki67 ( A ) and Cyclin D1 ( B ) staining. Both markers exhibited reduced staining in Kaiso Tg /+ mice compared to their Non-Tg siblings. Reduced CyclinD1 expression was also confirmed by immunoblot analysis of 3 different mice intestines ( C ). ** represents significance.

Article Snippet: Antibodies used were as follows: anti-Kaiso rabbit polyclonal antibody at a 1∶30,000 dilution, anti-Cyclin D1 rabbit polyclonal antibody (US Biological) at a 1∶5,000 dilution, anti-β-actin mouse monoclonal antibody (Sigma Aldrich) at a 1∶30,000 dilution.

Techniques: Staining, Expressing, Western Blot

Journal: Oncology Reports

Article Title: Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway

doi: 10.3892/or.2018.6198

Figure Lengend Snippet: The gemcitabine-erlotinib (E+G) combination group inhibits the activity of the JAK-STAT pathway, as well as the expression of downstream HIF-1α, cyclin D1 and p53. (A and B) The protein levels of phosphorylated STAT3 Tyr 705 (p-STAT3 Tyr 705 ), HIF-1α, p53, cyclin D1 in BxPC-3 and PANC-1 cells were analyzed by western blotting, respectively. (C and D) The protein expression of p-STAT3 Tyr 705 , HIF-1α, p53, cyclin D1 in BxPC-3 and PANC-1 cells was calculated using one-way ANOVA. *P<0.05 denotes the controls vs. the treatment groups. # P<0.05 denotes the monotherapy (E or G) vs. the combination (E+G) groups. (E) Phosphorylation levels of JAK1 (Tyr 1022 ), JAK2 (Tyr 221 ), JAK3(Tyr 981 ) and STAT3 (Tyr 701 ) in BxPC-3 and PANC-1 cells were analyzed by western blotting, respectively. (F and G) The protein intensity of phospho-JAK1 (p-JAK1), p-JAK2 and p-JAK3 in BxPC-3 and PANC-1 cells was calculated using one-way ANOVA. # P<0.01; *P<0.05. (H) The protein intensity of p-STAT1 in BxPC-3 and PANC-1 cells was assessed using one-way ANOVA. # P<0.01, *P<0.05. E, erlotinib; G, gemcitabine.

Article Snippet: The following primary antibodies were used: anti-JAK1 (rabbit polyclonal; cat. no. AF5012), phospho-JAK1 (Tyr 1022 ) (rabbit polyclonal; cat. no. AF2012), anti-JAK2 (rabbit polyclonal; cat. no. AF6022), phospho-JAK2 (Tyr 221 ) (rabbit polyclonal; cat. no. AF3023), anti-JAK3 (mouse monoclonal; cat. no. BF0256), phospho-JAK3 (Tyr 981 ) (rabbit polyclonal; cat. no. AF8160), phospho-STAT1 (Tyr 701 ) (rabbit polyclonal; cat. no. AF3300) and anti-STAT1 (rabbit polyclonal; cat. no. AF6300) were all purchased from Affinity Biosciences (Cambridge, UK); anti-STAT3 (rabbit monoclonal; cat. no. ab76315), and anti-pSTAT3 Try 705 (rabbit monoclonal; cat. no. ab68153) were obtained from Abcam (Cambridge, MA, USA); anti-HIF-1α (rabbit polyclonal; cat. no. BS3514) and anti-cyclin D1 (rabbit polyclonal; cat. no. BS6532) were purchased from Bioworld Technology Co., Ltd. (Nanjing, China); anti-p53 (rabbit, monoclonal; cat. no. 2527) was acquired from Cell Signaling Technology, Inc. (Danvers, MA, USA); while GAPDH was purchased from EarthOx Life Sciences (Millbrae, CA, USA).

Techniques: Activity Assay, Expressing, Western Blot